Both BRCA2 and STARD13 are well known tumor-suppressors, and upregulation of N4BP2L1 and N4BP2L2 has been associated with positive prognosis in ovarian cancer cases [56]. This evidence concerns the gene BRCA2 and ovarian carcinoma.